Profile data is unavailable for this security.
About the company
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
- Revenue in SEK (TTM)10.86m
- Net income in SEK-17.41m
- Incorporated2014
- Employees2.00
- LocationElicera Therapeutics ABWorld Trade Center Goteborg,Massans gata 10, van 7GOETEBORG 412 51SwedenSWE
- Phone+46 703319051
- Websitehttps://www.elicera.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Odi Pharma AB (publ) | 8.97m | -4.72m | 74.05m | 1.00 | -- | 253.14 | -- | 8.25 | -0.2851 | -0.2851 | 0.5266 | 0.016 | 1.33 | -- | 5.29 | 8,971,460.00 | -70.09 | -40.68 | -1,151.76 | -60.97 | -29.08 | -- | -52.61 | -95.17 | -- | -8.51 | 0.00 | -- | -85.94 | -- | -944.49 | -- | -- | -- |
| Oncozenge AB | 2.71m | -15.94m | 77.91m | 1.00 | -- | 9.19 | -- | 28.72 | -1.28 | -1.28 | 0.2238 | 0.6703 | 0.1514 | -- | 1.77 | -- | -88.96 | -49.16 | -122.96 | -55.02 | -- | -- | -587.54 | -3,418.24 | -- | -103.87 | 0.4694 | -- | -- | -- | -83.47 | -- | -- | -- |
| StenoCare A/S | 8.10m | -35.09m | 83.65m | 8.00 | -- | 23.62 | -- | 10.33 | -0.8176 | -0.8176 | 0.1569 | 0.0572 | 0.324 | -- | 3.80 | 709,217.50 | -140.37 | -45.69 | -201.07 | -59.64 | -- | -- | -433.19 | -739.04 | 1.32 | -6.51 | 0.526 | -- | -40.60 | -14.70 | -96.30 | -- | -64.95 | -- |
| Arctic Bioscience AS | 41.74m | -41.16m | 84.44m | 22.00 | -- | 0.4539 | -- | 2.02 | -1.67 | -1.67 | 1.69 | 7.27 | 0.156 | 0.9957 | 4.02 | 1,998,510.00 | -15.39 | -15.49 | -18.84 | -17.83 | 28.45 | 28.52 | -98.62 | -125.49 | 0.3389 | -9.68 | 0.2202 | -- | 28.84 | 7.68 | -5.31 | -- | -- | -- |
| Vivesto AB | 0.00 | -35.72m | 89.68m | 4.00 | -- | 0.3263 | -- | -- | -0.0664 | -0.0664 | 0.00 | 0.2483 | 0.00 | -- | -- | 0.00 | -21.35 | -- | -23.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.12 | -- | -- | -- |
| IRLAB Therapeutics AB | 57.46m | -110.01m | 145.79m | 31.00 | -- | 4.75 | -- | 2.54 | -1.75 | -1.75 | 0.8494 | 0.3617 | 0.4188 | -- | 11.05 | 1,853,613.00 | -80.18 | -31.73 | -328.93 | -40.78 | -72.94 | -33.99 | -191.45 | -101.39 | -- | -5.62 | 0.4937 | -- | -39.28 | -- | -32.34 | -- | -- | -- |
| Magle Chemoswed Holding AB | 292.44m | -26.60m | 165.20m | 144.00 | -- | 0.3107 | 5.96 | 0.5649 | -1.29 | -1.29 | 14.56 | 25.75 | 0.3085 | -0.0596 | 8.14 | 1,989,374.00 | -2.81 | 2.43 | -3.45 | 3.45 | 102.66 | 88.63 | -9.09 | 4.76 | 0.8205 | -0.1043 | 0.3887 | 0.00 | 38.49 | 13.10 | -1.91 | 74.06 | -21.72 | -- |
| Isofol Medical AB (publ) | 0.00 | -54.17m | 199.59m | 6.00 | -- | -- | -- | -- | -0.246 | -0.246 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -50.03 | -- | -64.52 | -- | -- | -- | -1,377.23 | -- | -- | -- | -- | -- | -- | -24.56 | -- | -- | -- |
| Elicera Therapeutics AB | 10.86m | -17.41m | 299.46m | 2.00 | -- | 12.82 | -- | 27.59 | -0.4128 | -0.4128 | 0.2696 | 0.4813 | 0.3948 | -- | 5.80 | 5,427,590.00 | -63.31 | -46.13 | -78.88 | -59.33 | -- | -- | -160.35 | -270.46 | -- | -- | -- | -- | 52.28 | -- | -8.05 | -- | -- | -- |
| Lipum AB (publ) | 0.00 | -76.37m | 307.58m | 6.00 | -- | -- | -- | -- | -3.60 | -3.60 | 0.00 | -1.33 | 0.00 | -- | -- | 0.00 | -179.79 | -146.87 | -660.20 | -220.28 | -- | -- | -- | -1,379,275.00 | -- | -39.82 | 3.77 | -- | -- | -- | -49.32 | -- | -- | -- |
| Biohit Oyj | 167.48m | 28.80m | 323.34m | 46.00 | 13.95 | 2.53 | 8.91 | 1.93 | 0.1778 | 0.1778 | 1.03 | 0.9804 | 0.8895 | 5.36 | 4.61 | 341,304.30 | 15.86 | 9.67 | 19.52 | 12.32 | 68.79 | 65.69 | 17.83 | 9.82 | 2.31 | -- | 0.097 | 0.00 | 9.92 | 17.12 | 5.14 | -- | 109.13 | -- |
| Corline Biomedical AB | 7.65m | -14.71m | 405.97m | 12.00 | -- | 4.33 | -- | 53.06 | -0.5929 | -0.5929 | 0.3093 | 3.66 | 0.0792 | -- | 5.89 | 637,583.30 | -15.22 | -9.29 | -16.29 | -10.07 | 81.36 | 109.32 | -192.31 | -60.64 | -- | -- | -- | -- | -21.73 | 15.66 | 36.56 | -- | -35.49 | -- |
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Mar 2025 | 3.98k | 0.01% |
